Advertisement

Ophthalmic complications of immune checkpoint inhibitor therapy for metastatic ovarian cancer

Published:March 14, 2022DOI:https://doi.org/10.1016/j.jcjo.2022.02.020
      A 69-year-old female reported 2 weeks of bilateral blurred vision. She had metastatic ovarian carcinoma and had been enrolled in a randomized, controlled trial of niraparib and dostarlimab/placebo. This was paused for 11 days because of drug-induced hepatitis.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect